BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14514975)

  • 1. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
    Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
    Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
    Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
    Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
    Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA6: a new predictor for prognosis in ovarian cancer.
    Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J
    Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
    Borgoño CA; Fracchioli S; Yousef GM; Rigault de la Longrais IA; Luo LY; Soosaipillai A; Puopolo M; Grass L; Scorilas A; Diamandis EP; Katsaros D
    Int J Cancer; 2003 Sep; 106(4):605-610. PubMed ID: 12845660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma.
    Yang G; He W; Cai M; Luo F; Kung H; Guan X; Zeng Y; Xie D
    Int J Gynecol Cancer; 2011 Apr; 21(3):486-93. PubMed ID: 21436696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
    Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
    Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
    Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
    Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
    Matuura H; Miyamoto M; Takano M; Soyama H; Aoyama T; Yoshikawa T; Kato K; Sakamoto T; Kuwahara M; Takasaki K; Ishibashi H; Iwahashi H; Tsuda H; Furuya K
    Anticancer Res; 2018 Feb; 38(2):717-722. PubMed ID: 29374695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas.
    Ross JS; Sheehan CE; Williams SS; Malfetano JH; Szyfelbein WM; Kallakury BV
    Am J Clin Pathol; 2001 Jul; 116(1):122-8. PubMed ID: 11447742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
    Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
    Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
    Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.
    Kayastha S; Freedman AN; Piver MS; Mukkamalla J; Romero-Guittierez M; Werness BA
    Clin Cancer Res; 1999 May; 5(5):1073-6. PubMed ID: 10353740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic analysis of ovarian cancer associated with endometriosis.
    Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
    Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.